Abstract：
Rifaximin, a broad-spectrum antibiotic, boasts a unique chemical composition and pharmacokinetic profile, rendering it highly effective in treating irritable bowel syndrome (IBS). Its minimal systemic absorption confines its impact to the gastrointestinal (GI) tract, where it yields significant therapeutic benefits. This review examines rifaximin\'s physico-chemical attributes and its role in managing IBS symptoms. Its molecular structure facilitates intestinal lumen retention postoral administration, minimizing systemic exposure and adverse effects. This targeted action is crucial in addressing the gut microbiota\'s role in IBS pathophysiology. By modifying microbial populations and their metabolite production, rifaximin mitigates symptoms like bloating, irregular bowel habits, and abdominal pain associated with IBS. It achieves this by reducing pathogenic bacteria and altering bacterial metabolism, enhancing mucosal and immune function. Clinical trials affirm rifaximin\'s superiority over placebo and conventional therapies in alleviating overall IBS symptoms and addressing small intestine bacterial overgrowth (SIBO). Despite its promising efficacy and sustained symptom relief, further research is essential to optimize long-term effectiveness and dosing regimens. Rifaximin stands as a vital treatment option for IBS due to its distinctive properties and clinical utility; yet, ongoing investigation is imperative for maximizing its therapeutic benefits.
摘要：
利福昔明,广谱抗生素,拥有独特的化学成分和药代动力学特征，使其在治疗肠易激综合征（IBS）方面非常有效。其最小的全身吸收将其影响限制在胃肠道（GI），在那里它产生显著的治疗益处。这篇综述探讨了利福昔明的理化特性及其在治疗IBS症状中的作用。其分子结构有利于肠腔保留后给药，尽量减少全身暴露和不利影响。这种靶向作用对于解决肠道微生物群在IBS病理生理学中的作用至关重要。通过改变微生物种群及其代谢物的产生，利福昔明缓解腹胀等症状,不规则的排便习惯,与IBS相关的腹痛。它通过减少致病菌和改变细菌代谢来实现这一目标，增强粘膜和免疫功能。临床试验证实利福昔明在减轻整体IBS症状和解决小肠细菌过度生长（SIBO）方面优于安慰剂和常规疗法。尽管它有希望的疗效和持续的症状缓解，进一步的研究对于优化长期有效性和给药方案至关重要.利福昔明由于其独特的特性和临床实用性而成为IBS的重要治疗选择；然而，正在进行的调查对于最大限度地提高其治疗效益至关重要.
